Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Gadobutrol Enhanced MRA of the Supra-aortic Vessels (GEMSAV)

10 grudnia 2018 zaktualizowane przez: Bayer

Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels

Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required.

This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study.

MRA and CTA images will be collected for an independent review (blinded read).

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

479

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Argentyna
    • Buenos Aires
      • Adrogué, Buenos Aires, Argentyna, B1846DWA
    • Ciudad Auton. De Buenos Aires
      • Buenos Aires, Ciudad Auton. De Buenos Aires, Argentyna, C1115AAB
      • Buenos Aires, Ciudad Auton. De Buenos Aires, Argentyna, C1425BEE
  • Australia
    • New South Wales
      • New Lambton Heights, New South Wales, Australia, 2305
    • Victoria
      • Clayton, Victoria, Australia, 3168
      • Parkville, Victoria, Australia, 3052
  • Austria
      • Wien, Austria, 1090
    • Tirol
      • Innsbruck, Tirol, Austria, 6020
  • Chiny
      • Shanghai, Chiny, 200032
      • Shanghai, Chiny, 200433
  • Czechy
      • Brno, Czechy, 62500
  • Francja
      • BRON Cedex, Francja, 69677
      • Brest Cedex, Francja, 29609
      • Marseille, Francja, 13385
      • Paris, Francja, 75877
      • Paris Cedex 15, Francja, 75908
  • Indyk
      • Antalya, Indyk, 07059
      • Erzurum, Indyk, 25240
      • Istanbul, Indyk, 34093
  • Niemcy
    • Baden-Württemberg
      • Karlsruhe, Baden-Württemberg, Niemcy, 76133
    • Bayern
      • Augsburg, Bayern, Niemcy, 865156
      • Erlangen, Bayern, Niemcy, 91054
    • Nordrhein-Westfalen
      • Münster, Nordrhein-Westfalen, Niemcy, 48145
    • Thüringen
      • Jena, Thüringen, Niemcy, 07740
  • Polska
      • Bydgoszcz, Polska, 85-094
      • Lodz, Polska, 90-153
      • Warszawa, Polska, 02-097
      • Wroclaw, Polska, 50-556
  • Republika Korei
      • Seoul, Republika Korei, 05505
      • Seoul, Republika Korei, 06351
      • Seoul, Republika Korei, 03722
    • Gwangju Gwang''yeogsi
      • Donggu,, Gwangju Gwang''yeogsi, Republika Korei, 61469
  • Stany Zjednoczone
    • Arizona
      • Tucson, Arizona, Stany Zjednoczone, 85724
    • Florida
      • Jacksonville, Florida, Stany Zjednoczone, 32209
    • Georgia
      • Savannah, Georgia, Stany Zjednoczone, 31406
    • Kentucky
      • Louisville, Kentucky, Stany Zjednoczone, 40202
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21201
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02114
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48109-0330
    • Mississippi
      • Jackson, Mississippi, Stany Zjednoczone, 39216
    • New York
      • Bronx, New York, Stany Zjednoczone, 10467
      • Rochester, New York, Stany Zjednoczone, 14642
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
    • Rhode Island
      • Providence, Rhode Island, Stany Zjednoczone, 02903
    • Tennessee
      • Memphis, Tennessee, Stany Zjednoczone, 38104
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98195
    • Wisconsin
      • Madison, Wisconsin, Stany Zjednoczone, 53792
  • Szwajcaria
    • Sankt Gallen
      • St. Gallen, Sankt Gallen, Szwajcaria, 9007
  • Szwecja
      • Linköping, Szwecja, 581 85
      • Uppsala, Szwecja, 751 85
  • Włochy
    • Emilia-Romagna
      • Ferrara, Emilia-Romagna, Włochy, 44023
    • Lazio
      • Roma, Lazio, Włochy, 00168
    • Sicilia
      • Catania, Sicilia, Włochy, 95123
    • Toscana
      • Massa-Carrara, Toscana, Włochy, 54100
    • Valle d'Aosta
      • Aosta, Valle d'Aosta, Włochy, 11100
    • Veneto
      • Venezia, Veneto, Włochy, 30174

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Male or female subjects, aged 18 years and older

  • Any of the following:

    • Known or suspected supra-aortic arterial disease based on:

      • Prior stroke
      • Transient ischemic attack (TIA)
      • Amaurosis Fugax (transient monocular blindness)
    • Referred for evaluation of any supra-aortic vessel (for clinically significant stenosis)
    • Follow-up for a stent in a supra-aortic vessel
    • Prior imaging study (CTA or ultrasound) showing ≥ 50% stenosis of a supra-aortic vessel segment (within 60 days before consent). The proportion of subjects with positive disease (determined by the investigator, based on CTA or ultrasound) will be monitored during the study, and enrolment may be further restricted to require ≥ 70% stenosis to ensure that overall there are an adequate number of subjects with clinically significant disease for the evaluation of study endpoints.
  • Willingness to undergo the routine Contrast Enhanced Magnetic Resonance Angiography [CE MRA] examination with gadobutrol
  • Willingness and ability to follow directions and complete all study procedures specified in the protocol
  • Females of childbearing potential only: Negative pregnancy test on the day of the MRA before the administration of study drug

Exclusion Criteria:

  • Pregnant or nursing (including pumping for storage and feeding)
  • Received any other investigational product or participation in any other clinical trial within 30 days before enrollment into this study
  • Previous enrollment into this study or into any other Bayer sponsored study using gadobutrol
  • Contraindication to the MRA examinations (e.g. inability to hold breath; severe arrhythmias; very low cardiac output, severe claustrophobia, defibrillators or other metallic devices not approved for MRI)
  • Contraindication to the use of Gd-containing contrast agents (including subjects with suspicion for or known to have Nephrogenic Systemic Fibrosis [NSF])
  • History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents
  • Received any contrast agent within 72 hours before the study MRA, or scheduled receipt of any contrast agent within 24 hours after the study MRA (Note: This applies also to a CTA potentially scheduled during the course of the study.)
  • Estimated glomerular filtration rate (eGFR) value < 30 ml/min/1.73 m2 derived from a serum creatinine result within 2 weeks before the gadobutrol injection. Any subject on hemodialysis or peritoneal dialysis is excluded from participation. Use the value obtained prior to and closest to the time of the MRA, if there are multiple creatinine values. (Do not use the core lab value if not available prior to the MRA.)
  • Acute renal insufficiency of any intensity, either due to hepato-renal syndrome or occurring in the peri-operative liver transplantation period
  • Severe cardiovascular disease (e.g. acute myocardial infarction [< 14 days], unstable angina, congestive heart failure New York Heart Association class IV) or known long QT syndrome
  • Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery)

  • Scheduled or potentially expected for the period between the CTA and gadobutrol MRA:

    • Any procedure that may alter the MRA or CTA interpretation, or
    • Any interventional or surgical procedure involving the supra-aortic vessels

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Diagnostyczny
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Ramię 1
Lek: Gadobutrol (Gadovist, BAY86-4875)
A single bolus injection of approx. 0.1mmol/kg

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Ramy czasowe: Images were taken pre-injection and post-injection
Each vascular segment was visualized using unenhanced MRA and gadobutrol-enhanced MRA, characterized by the on-site investigators, three independent blinded readers (BR) (BR 1, BR 2 and BR 3) and majority readers (the outcome determined by at least two of the blinded readers). A segment was assessable if it was visualized along its entire length and if any region of stenosis, was measured reliably. There were 21 segments of the supra-aortic arteries assessed per participant.
Images were taken pre-injection and post-injection
Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Ramy czasowe: Images were taken pre-injection and post-injection
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the standard of reference (SoR) (computed tomographic angiography [CTA]; blinded readers). This was determined using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.
Images were taken pre-injection and post-injection
Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Ramy czasowe: Images were taken pre-injection and post-injection
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the SoR (CTA; blinded readers). This was determined using the NASCET criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.
Images were taken pre-injection and post-injection
Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%
Ramy czasowe: Images were taken pre-injection and post-injection
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.
Images were taken pre-injection and post-injection
Minimum Gadobutrol Performance for Specificity: Specificity > 50%
Ramy czasowe: Images were taken pre-injection and post-injection
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.
Images were taken pre-injection and post-injection

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Procent segmentów z obecnością artefaktów
Ramy czasowe: Zdjęcia wykonano przed iniekcją i po iniekcji
Artefakty zostały zebrane dla obrazów MRA na zasadzie segmentacji.
Zdjęcia wykonano przed iniekcją i po iniekcji
Rodzaje dodatkowych badań obrazowych zalecane przez badacza klinicznego po ocenie obrazów MRA bez wzmocnienia i wzmocnionego gadobutrolem
Ramy czasowe: Zdjęcia wykonano przed iniekcją i po iniekcji
Dodatkowe zalecane badanie obrazowe zostało określone z następującej listy: MRA bez kontrastu, MRA ze wzmocnieniem kontrastowym, CTA, USG, angiogram z cyfrowym cewnikiem subtrakcyjnym (DSCA) i badanie medycyny nuklearnej.
Zdjęcia wykonano przed iniekcją i po iniekcji
Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images
Ramy czasowe: Images were taken pre-injection and post-injection
The segment reduction in diameter (DIA) of greater than 10% was considered abnormal and measured. The diameter of each of these abnormal segments was measured using electronic calipers (perpendicular to the long axis of the vessel) at the point of most severe stenosis within each segment. Mean of vessel diameters was calculated by segment separately for CTA and MRA readers. For ease of expression, the following abbreviations will be used: Diameter (DIA), Blinded Reader (BR), Clinical Investigator (CI).
Images were taken pre-injection and post-injection
Types of Artifacts on a Segment Basis by Blinded Reader 1
Ramy czasowe: Images were taken pre-injection and post-injection
The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example [eg], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).
Images were taken pre-injection and post-injection
Types of Artifacts on a Segment Basis by Blinded Reader 2
Ramy czasowe: Images were taken pre-injection and post-injection
The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example [eg], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).
Images were taken pre-injection and post-injection
Types of Artifacts on a Segment Basis by Blinded Reader 3
Ramy czasowe: Images were taken pre-injection and post-injection
The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example [eg], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).
Images were taken pre-injection and post-injection
The Percentage of Location of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA
Ramy czasowe: Images were taken pre-injection and post-injection
Location within a segment was based on the point of greatest stenosis and was recorded for stenosis >=70% (including occlusions) as: - At the bifurcation or proximal origin of a segment (occlusion proximal to the origin of the segment); - Within 5 mm of the bifurcation or proximal origin of a segment; - Beyond 5 mm from the bifurcation or proximal origin of a segment.
Images were taken pre-injection and post-injection
Length of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA
Ramy czasowe: Images were taken pre-injection and post-injection
The length of stenosis was based on the most proximal (first point) in a segment where a stenosis exceeded 10% and the most distal point (last point) in the segment where a stenosis exceeded 10%. If a stenosis spanned more than one segment then the measurement was only included to the beginning or end (boundary) of the segment being evaluated. If there was no stenosis of >=70% in a segment then the length was designated as 0.
Images were taken pre-injection and post-injection
The Percentage of Presence of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease
Ramy czasowe: Images were taken pre-injection and post-injection
Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present.
Images were taken pre-injection and post-injection
Type of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease
Ramy czasowe: Images were taken pre-injection and post-injection
Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present. If there were tandem (serial) stenosis in a vessel then the secondary signs were assigned to the stenosis of >=70% that was proximal and closest in proximity to the secondary sign.
Images were taken pre-injection and post-injection
Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Ramy czasowe: Images were taken pre-injection and post-injection
Diagnostic confidence was evaluated to determine the level of certainty that the blinded readers assigned to a diagnosis for each segment. This was defined as the degree of confidence that the information on the MRA images represented the true and complete clinical picture of a particular segment. The degree of confidence was rated on a 4-point scale: 1 = Not confident, 2 = Somewhat confident, 3 = Confident, and 4 = Very confident.
Images were taken pre-injection and post-injection
The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images
Ramy czasowe: Images were taken pre-injection and post-injection
A measure of diagnostic value was the reduction in the number of additional diagnostic imaging studies recommended/ordered. The clinical investigators and the blinded readers were asked if they would have recommended an additional imaging study for each participant and was recorded.
Images were taken pre-injection and post-injection
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 1
Ramy czasowe: Images were taken pre-injection and post-injection
An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.
Images were taken pre-injection and post-injection
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 2
Ramy czasowe: Images were taken pre-injection and post-injection
An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.
Images were taken pre-injection and post-injection
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 3
Ramy czasowe: Images were taken pre-injection and post-injection
An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.
Images were taken pre-injection and post-injection

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Bayer

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

12 maja 2011

Zakończenie podstawowe (Rzeczywisty)

28 maja 2014

Ukończenie studiów (Rzeczywisty)

28 maja 2014

Daty rejestracji na studia

Pierwszy przesłany

5 kwietnia 2011

Pierwszy przesłany, który spełnia kryteria kontroli jakości

28 kwietnia 2011

Pierwszy wysłany (Oszacować)

29 kwietnia 2011

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 stycznia 2019

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 grudnia 2018

Ostatnia weryfikacja

1 grudnia 2018

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 14607
  • 2010-023001-36 (Numer EudraCT)

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Gadobutrol (Gadovist, BAY86-4875)

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Singapore

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj